ATC
BBNX icon

Adirondack Trust Company’s Beta Bionics BBNX Stock Holding History

Adirondack Trust Company’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.45K Buy
+603
New +$7.17K ﹤0.01% 420

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Adirondack Trust Company's BBNX Position: Q2 2026 in Review

Adirondack Trust Company opened a new position in Beta Bionics (BBNX) in Q2 2026: 603 shares worth $9.45K. The stake represents ﹤0.01% of the portfolio and ranks #420 among its holdings.

133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Adirondack Trust Company held 603 shares of Beta Bionics worth $9.45K as of Q2 2026.
  • Beta Bionics was a new Adirondack Trust Company position in Q2 2026.
  • Beta Bionics made up ﹤0.01% of Adirondack Trust Company's portfolio in Q2 2026, its #420 holding.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Adirondack Trust Company's 13F filing for Q2 2026, filed 16 Jul 2026.